Nuvation Bio Faces More Predictable Growth Supported by Ibtrozi Frontline Adoption, Wedbush Says

MT Newswires Live07-01

Nuvation Bio's (NUVB) Q2 results will be an important checkpoint for Ibtrozi's commercial launch as it transitions to a "more durable, frontline-driven growth profile," with investors eyeing revenue variability, Wedbush said in a note Tuesday.

The brokerage said it expects quarterly revenue to become "materially more predictable" over the coming quarters, as the mix continues to skew toward treatment-naive patients with median duration of response of about four years.

The firm forecasts Q2 Ibtrozi revenue of $22.2 million, up 20% sequentially, and full-year 2026 revenue of $122.3 million. Wedbush also noted that safusidenib remains an "underappreciated long-term value driver."

The firm reiterated its outperform rating on the stock with $11 price target.

Price: 5.74, Change: +0.13, Percent Change: +2.23

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2648569313?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-01 03:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648569313","market":"nz","top_or_hot":-1,"title":"Nuvation Bio Faces More Predictable Growth Supported by Ibtrozi Frontline Adoption, Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NUVB\">Nuvation Bio</a>'s (NUVB) Q2 results will be an important checkpoint for Ibtrozi's commercial launch as it transitions to a \"more durable, frontline-driven growth profile,\" with investors eyeing revenue variability, Wedbush said in a note Tuesday.</p><p>The brokerage said it expects quarterly revenue to become \"materially more predictable\" over the coming quarters, as the mix continues to skew toward treatment-naive patients with median duration of response of about four years.</p><p>The firm forecasts Q2 Ibtrozi revenue of $22.2 million, up 20% sequentially, and full-year 2026 revenue of $122.3 million. Wedbush also noted that safusidenib remains an \"underappreciated long-term value driver.\"</p><p>The firm reiterated its outperform rating on the stock with $11 price target.</p><p>Price: 5.74, Change: +0.13, Percent Change: +2.23</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuvation Bio Faces More Predictable Growth Supported by Ibtrozi Frontline Adoption, Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuvation Bio Faces More Predictable Growth Supported by Ibtrozi Frontline Adoption, Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-01 03:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NUVB\">Nuvation Bio</a>'s (NUVB) Q2 results will be an important checkpoint for Ibtrozi's commercial launch as it transitions to a \"more durable, frontline-driven growth profile,\" with investors eyeing revenue variability, Wedbush said in a note Tuesday.</p><p>The brokerage said it expects quarterly revenue to become \"materially more predictable\" over the coming quarters, as the mix continues to skew toward treatment-naive patients with median duration of response of about four years.</p><p>The firm forecasts Q2 Ibtrozi revenue of $22.2 million, up 20% sequentially, and full-year 2026 revenue of $122.3 million. Wedbush also noted that safusidenib remains an \"underappreciated long-term value driver.\"</p><p>The firm reiterated its outperform rating on the stock with $11 price target.</p><p>Price: 5.74, Change: +0.13, Percent Change: +2.23</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NUVB","symbol_name":"Nuvation Bio, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2648569313","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2648569313","pubTimestamp":1782846488,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Nuvation Bio's  Q2 results will be an important checkpoint for Ibtrozi's commercial launch as it transitions to a \"more durable, frontline-driven growth profile,\" with investors eyeing revenue variability, Wedbush said in a note Tuesday.The brokerage said it expects quarterly revenue to become \"materially more predictable\" over the coming quarters, as the mix continues to skew toward treatment-naive patients with median duration of response of about four years.The firm forecasts Q2 Ibtrozi revenue of $22.2 million, up 20% sequentially, and full-year 2026 revenue of $122.3 million. Wedbush also noted that safusidenib remains an \"underappreciated long-term value driver.\"The firm reiterated its outperform rating on the stock with $11 price target.Price: 5.74, Change: +0.13, Percent Change: +2.23","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NUVB":"Nuvation Bio, Inc.","BK4007":"制药"},"translate_title":"Wedbush表示，在Ibtrozi前线采用的支持下，Nuvation Bio面临更可预测的增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NUVB":1},"content_text":"Nuvation Bio's (NUVB) Q2 results will be an important checkpoint for Ibtrozi's commercial launch as it transitions to a \"more durable, frontline-driven growth profile,\" with investors eyeing revenue variability, Wedbush said in a note Tuesday.The brokerage said it expects quarterly revenue to become \"materially more predictable\" over the coming quarters, as the mix continues to skew toward treatment-naive patients with median duration of response of about four years.The firm forecasts Q2 Ibtrozi revenue of $22.2 million, up 20% sequentially, and full-year 2026 revenue of $122.3 million. Wedbush also noted that safusidenib remains an \"underappreciated long-term value driver.\"The firm reiterated its outperform rating on the stock with $11 price target.Price: 5.74, Change: +0.13, Percent Change: +2.23","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648569313","isCrawlerRequest":true}